Vascular damaging agents
- PMID: 17459681
- DOI: 10.1016/j.clon.2007.03.014
Vascular damaging agents
Abstract
To provide a comprehensive overview on vascular targeting agents and the application of radiobiological principles in pre-clinical and clinical studies, we completed a comprehensive review of published medical studies on vascular targeting agents using Pub Med. Vascular targeting agents are now divided into vascular disrupting agents (VDAs), which target the pre-existing tumour vasculature, and angiogenesis inhibitors (AIs), which prevent the formation of new blood vessels. Modest success has been seen when VDAs and AIs are used as single agents and therefore combination therapies that can work in a complimentary and synergistic manner, targeting both the tumour cells and endothelial cells, are needed. Radiobiological principles have been used to increase our understanding of these agents, and can explain the increased efficacy of combination treatments. In particular, the alteration of the tumour microenvironment by AIs and VDAs can lead to enhanced efficacy when combined with chemotherapy or radiotherapy, with phase II/III trials showing encouraging results. The optimal use and scheduling of AIs and VDAs remains to be determined. Further understanding of the mechanisms of action of these potentially very exciting anti-neoplastic agents is urgently required.
Similar articles
-
Vascular targeting therapy: potential benefit depends on tumor and host related effects.Exp Oncol. 2010 Sep;32(3):143-8. Exp Oncol. 2010. PMID: 21403608 Review.
-
Current development status of small-molecule vascular disrupting agents.Curr Opin Investig Drugs. 2006 Jun;7(6):522-8. Curr Opin Investig Drugs. 2006. PMID: 16784022 Review.
-
Drug insight: vascular disrupting agents and angiogenesis--novel approaches for drug delivery.Nat Clin Pract Oncol. 2006 Dec;3(12):682-92. doi: 10.1038/ncponc0663. Nat Clin Pract Oncol. 2006. PMID: 17139319 Review.
-
Angiogenesis and vascular targeting: relevance for hyperthermia.Int J Hyperthermia. 2008 Feb;24(1):57-65. doi: 10.1080/02656730701829710. Int J Hyperthermia. 2008. PMID: 18214769 Review.
-
The development of the tumor vascular-disrupting agent ASA404 (vadimezan, DMXAA): current status and future opportunities.Expert Opin Investig Drugs. 2010 Feb;19(2):295-304. doi: 10.1517/13543780903540214. Expert Opin Investig Drugs. 2010. PMID: 20050824
Cited by
-
Vascular disrupting action of electroporation and electrochemotherapy with bleomycin in murine sarcoma.Br J Cancer. 2008 Jan 29;98(2):388-98. doi: 10.1038/sj.bjc.6604168. Epub 2008 Jan 8. Br J Cancer. 2008. PMID: 18182988 Free PMC article.
-
Vascular effects of plinabulin (NPI-2358) and the influence on tumour response when given alone or combined with radiation.Int J Radiat Biol. 2011 Nov;87(11):1126-34. doi: 10.3109/09553002.2011.605418. Int J Radiat Biol. 2011. PMID: 21815749 Free PMC article.
-
Bioreductively Activatable Prodrug Conjugates of Combretastatin A-1 and Combretastatin A-4 as Anticancer Agents Targeted toward Tumor-Associated Hypoxia.J Nat Prod. 2020 Apr 24;83(4):937-954. doi: 10.1021/acs.jnatprod.9b00773. Epub 2020 Mar 20. J Nat Prod. 2020. PMID: 32196334 Free PMC article.
-
Regioselective synthesis of water-soluble monophosphate derivatives of combretastatin A-1.J Nat Prod. 2011 Jul 22;74(7):1568-74. doi: 10.1021/np200104t. Epub 2011 Jun 30. J Nat Prod. 2011. PMID: 21718055 Free PMC article.
-
Tumor vascular infarction: prospects and challenges.Int J Hematol. 2017 Mar;105(3):244-256. doi: 10.1007/s12185-016-2171-3. Epub 2017 Jan 2. Int J Hematol. 2017. PMID: 28044258 Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
